|
gptkbp:instanceOf
|
gptkb:chemical_compound
recreational drug
|
|
gptkbp:actsOn
|
norepinephrine reuptake inhibitor
kappa-opioid receptor agonist
mu-opioid receptor partial agonist
|
|
gptkbp:CASNumber
|
6983-94-6
|
|
gptkbp:discovered_as_metabolite_in
|
1960s
|
|
gptkbp:foundIn
|
gptkb:Tabernanthe_iboga
|
|
gptkbp:has_potential_use_in
|
addiction treatment
depression treatment
|
|
gptkbp:has_psychoactive_effects
|
yes
|
|
gptkbp:hasInChIKey
|
QJQYQHNNWMOYPM-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C19H24N2O
|
|
gptkbp:hasSMILES
|
COc1cccc2c3CCN4CC(C2c13)CN=C4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
noribogaine
|
|
gptkbp:IUPACName
|
gptkb:12-methoxyibogamine
|
|
gptkbp:legalStatus
|
uncontrolled (most countries)
|
|
gptkbp:metabolite_of
|
gptkb:ibogaine
|
|
gptkbp:molecularWeight
|
296.41 g/mol
|
|
gptkbp:parent_compound
|
gptkb:ibogaine
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2103836
110246
123826
|
|
gptkbp:relatedTo
|
gptkb:18-MC
tabernanthine
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:UNII
|
6J8R1Y2V3E
|
|
gptkbp:bfsParent
|
gptkb:ibogaine
|
|
gptkbp:bfsLayer
|
6
|